Get started
Vaxcyte, Inc.Vaxcyte, Inc.Vaxcyte, Inc.

Vaxcyte, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

PCVX chart


Full chart

PCVX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.91 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.88 USD
Net income (FY)
‪−463.93 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪125.04 M‬
Beta (1Y)
1.86

Employees


Employees (FY)
414
Change (1Y)
+160 +62.99%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.12 M‬ USD

About Vaxcyte, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Grant E. Pickering
Website
vaxcyte.com
Headquarters
San Carlos
Founded
2013
FIGI
BBG009PHHPL8
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

PCVX news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as PCVX.

Frequently Asked Questions


The current price of PCVX is 33.59 USD — it has increased by 2.86% in the past 24 hours. Watch Vaxcyte, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vaxcyte, Inc. stocks are traded under the ticker PCVX.
PCVX stock has fallen by −2.89% compared to the previous week, the month change is a −57.56% fall, over the last year Vaxcyte, Inc. has showed a −45.65% decrease.
We've gathered analysts' opinions on Vaxcyte, Inc. future price: according to them, PCVX price has a max estimate of 163.00 USD and a min estimate of 65.00 USD. Watch PCVX chart and read a more detailed Vaxcyte, Inc. stock forecast: see what analysts think of Vaxcyte, Inc. and suggest that you do with its stocks.
PCVX reached its all-time high on Sep 19, 2024 with the price of 121.06 USD, and its all-time low was 15.51 USD and was reached on May 11, 2021. View more price dynamics on PCVX chart.
See other stocks reaching their highest and lowest prices.
PCVX stock is 9.76% volatile and has beta coefficient of 1.86. Track Vaxcyte, Inc. stock price on the chart and check out the list of the most volatile stocks — is Vaxcyte, Inc. there?
Today Vaxcyte, Inc. has the market capitalization of ‪4.03 B‬, it has decreased by −1.76% over the last week.
Yes, you can track Vaxcyte, Inc. financials in yearly and quarterly reports right on TradingView.
Vaxcyte, Inc. is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
PCVX earnings for the last quarter are −1.02 USD per share, whereas the estimation was −1.11 USD resulting in a 7.82% surprise. The estimated earnings for the next quarter are −1.06 USD per share. See more details about Vaxcyte, Inc. earnings.
Vaxcyte, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
PCVX net income for the last quarter is ‪−137.08 M‬ USD, while the quarter before that showed ‪−103.12 M‬ USD of net income which accounts for −32.93% change. Track more Vaxcyte, Inc. financial stats to get the full picture.
No, PCVX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 414 employees. See our rating of the largest employees — is Vaxcyte, Inc. on this list?
Like other stocks, PCVX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vaxcyte, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vaxcyte, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vaxcyte, Inc. stock shows the strong sell signal. See more of Vaxcyte, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.